- Scribe's $96M IPO; Scholar Rock awaits site classification for apitegromabScribe writes in $96M IPO: The gene editing biotech expects net proceeds of about $96 million if it prices its Nasdaq listing at $14 per share, the midpoint of the ...Endpoints · 4d ago↗ source
- J&J, AbbVie said to have also looked at AtaiBeckley before Lilly’s $2.8B dealJohnson & Johnson and AbbVie, the two pharma giants already in the psychedelic space, also eyed AtaiBeckley, according to a source familiar with the situation, but didn’t make an offer before E…Endpoints · 4d ago↗ source
- STAT+: The next step of site-neutral, and a fiery PBM hearingMedicare proposes to reduce payments to hospitals for certain drugs and imaging services.STAT · 4d ago